Cargando…

Basal cytokeratins in breast tumours among BRCA1, BRCA2 and mutation-negative breast cancer families

INTRODUCTION: Finding new immunohistochemical markers that are specific to hereditary breast cancer could help us to select candidates for BRCA1/BRCA2 mutation testing and to understand the biological pathways of tumour development. METHODS: Using breast cancer tumour microarrays, immunohistochemica...

Descripción completa

Detalles Bibliográficos
Autores principales:	Eerola, Hannaleena, Heinonen, Mira, Heikkilä, Päivi, Kilpivaara, Outi, Tamminen, Anitta, Aittomäki, Kristiina, Blomqvist, Carl, Ristimäki, Ari, Nevanlinna, Heli
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2008
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2374973/ https://www.ncbi.nlm.nih.gov/pubmed/18275599 http://dx.doi.org/10.1186/bcr1863

Ejemplares similares

Histopathological features of breast tumours in BRCA1, BRCA2 and mutation-negative breast cancer families
por: Eerola, Hannaleena, et al.
Publicado: (2005)

Relationship of patients' age to histopathological features of breast tumours in BRCA1 and BRCA2 and mutation-negative breast cancer families
por: Eerola, Hannaleena, et al.
Publicado: (2005)

Comprehensive analysis of NuMA variation in breast cancer
por: Kilpivaara, Outi, et al.
Publicado: (2008)

BACH1 Ser919Pro variant and breast cancer risk
por: Vahteristo, Pia, et al.
Publicado: (2006)

ATM variants and cancer risk in breast cancer patients from Southern Finland
por: Tommiska, Johanna, et al.
Publicado: (2006)

A probability model for predicting BRCA1 and BRCA2 mutations in breast and breast-ovarian cancer families
por: Vahteristo, P, et al.
Publicado: (2001)

Breast tumors from CHEK2 1100delC-mutation carriers: genomic landscape and clinical implications
por: Muranen, Taru A, et al.
Publicado: (2011)

Familial Breast Cancer in Southern Finland
por: Eerola, Hannaleena, et al.
Publicado: (1999)

Constitutional mosaicism for a BRCA2 mutation as a cause of early-onset breast cancer
por: Alhopuro, Pia, et al.
Publicado: (2020)

Variants on the promoter region of PTEN affect breast cancer progression and patient survival
por: Heikkinen, Tuomas, et al.
Publicado: (2011)

High cyclin B1 expression is associated with poor survival in breast cancer
por: Aaltonen, K, et al.
Publicado: (2009)

Genome-wide search for breast cancer linkage in large Icelandic non-BRCA1/2 families
por: Arason, Adalgeir, et al.
Publicado: (2010)

Pathogenic Variant Spectrum in Breast Cancer Risk Genes in Finnish Patients
por: Nurmi, Anna K., et al.
Publicado: (2022)

MiR-34a Expression Has an Effect for Lower Risk of Metastasis and Associates with Expression Patterns Predicting Clinical Outcome in Breast Cancer
por: Peurala, Hanna, et al.
Publicado: (2011)

Association of Cytokeratin 5 and Claudin 3 expression with BRCA1 and BRCA2 germline mutations in women with early breast cancer
por: Danzinger, Sabine, et al.
Publicado: (2019)

53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers
por: Bouwman, Peter, et al.
Publicado: (2010)

RAD51, XRCC3, and XRCC2 mutation screening in Finnish breast cancer families
por: Pelttari, Liisa M, et al.
Publicado: (2015)

Mast cells and eosinophils in invasive breast carcinoma
por: Amini, Rose-Marie, et al.
Publicado: (2007)

Genomic subtypes of breast cancer identified by array-comparative genomic hybridization display distinct molecular and clinical characteristics
por: Jönsson, Göran, et al.
Publicado: (2010)

MiRNAs prognostic for basal and BRCA1 breast cancer
por: Pal, Bhupinder, et al.
Publicado: (2018)

CHEK2 c.1100delC mutation is associated with an increased risk for male breast cancer in Finnish patient population
por: Hallamies, Sanna, et al.
Publicado: (2017)

Combined effect of CCND1 and COMT polymorphisms and increased breast cancer risk
por: Onay, Ummiye V, et al.
Publicado: (2008)

Meta-analysis of three genome-wide association studies identifies two loci that predict survival and treatment outcome in breast cancer
por: Khan, Sofia, et al.
Publicado: (2017)

High miR-30 Expression Associates with Improved Breast Cancer Patient Survival and Treatment Outcome
por: Jamshidi, Maral, et al.
Publicado: (2021)

Association of germline variation with the survival of women with BRCA1/2 pathogenic variants and breast cancer
por: Muranen, Taru A., et al.
Publicado: (2020)

BRCA1 transcriptionally regulates genes associated with the basal breast cancer phenotype
por: Quinn, JE, et al.
Publicado: (2006)

Polygenic risk score is associated with increased disease risk in 52 Finnish breast cancer families
por: Muranen, Taru A., et al.
Publicado: (2016)

Effects of BRCA2 cis-regulation in normal breast and cancer risk amongst BRCA2 mutation carriers
por: Maia, Ana-Teresa, et al.
Publicado: (2012)

Screening BRCA1 and BRCA2 Mutation Carriers for Breast Cancer
por: Warner, Ellen
Publicado: (2018)

BRCA1 mutations in women with familial or early-onset breast cancer and BRCA2 mutations in familial cancer in Estonia
por: Tamboom, Kristiina, et al.
Publicado: (2010)

Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2
por: Silvestri, Valentina, et al.
Publicado: (2016)

Phase 1 trial of olaparib and oral cyclophosphamide in BRCA breast cancer, recurrent BRCA ovarian cancer, non-BRCA triple-negative breast cancer, and non-BRCA ovarian cancer
por: Lee, Chee Khoon, et al.
Publicado: (2019)

Embryonic mammary signature subsets are activated in Brca1(-/- )and basal-like breast cancers
por: Zvelebil, Marketa, et al.
Publicado: (2013)

Increased gene expression variability in BRCA1-associated and basal-like breast tumours
por: Wiggins, George A. R., et al.
Publicado: (2021)

Mutations of the BRCA1 and BRCA2 genes in patients with bilateral breast cancer
por: Steinmann, D, et al.
Publicado: (2001)

Variation in breast cancer risk in BRCA1 and BRCA2 mutation carriers
por: Rebbeck, Timothy R, et al.
Publicado: (2008)

Are BRCA1- and BRCA2-related breast cancers associated with increased mortality?
por: Gareth Evans, D, et al.
Publicado: (2004)

Breast cancer prevention in women with a BRCA1 or BRCA2 mutation
por: Metcalfe, Kelly A, et al.
Publicado: (2007)

Risks of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers
por: Ahmed, M, et al.
Publicado: (2010)

Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers
por: Metcalfe, K, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_qgvnd26ofh03v09pctufl9q0h4